Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.
Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises
A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — and even some new potential upsides.
Ozempic and Other GLP-1s May Have Broader Health Benefits but Greater Risks
Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a risk to other vital organs.
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind
Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.
Ozempic can lower chances of multiple health conditions but comes with risks, study finds
Ozempic, Wegovy, Zepbound and other drugs often used for weight loss can help lower the risk of a wide range of health conditions, according to a new study. But the drugs also pose certain risks. Kyle Benning explains.
17h
on MSN
Ozempic May Lower Your Dementia Risk, New Study Suggests. A Neurologist Explains The Potential Link
Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially ...
19h
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...
STAT
1d
What can’t GLP-1s do? Study maps benefits while warning of uncommon risks
GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.
IFLScience
1d
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
19h
Gala Launches Revolutionary App for GLP-1 Medication Management, Serving Over 20,000 Patients
SAN FRANCISCO, CA / ACCESS Newswire / January 21, 2025 / Gala introduces a groundbreaking digital health platform that ...
1d
on MSN
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Hosted on MSN
6d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Employee Benefit News
6d
A guide to GLP-1 adoption: How employers can add this benefit in 2025
While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback